TGFB2 and systemic sclerosis: Taken together, these studies and our results reinforce the previously proposed idea that the lower TGFB2 blood expression of SSc-ILD patients is the consequence of a compensatory regulatory mechanism that represses gene expression because of overexpression at serum and tissue levels.